Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: Implications for cancer treatment

FASEB Journal

Volumn 29, Issue 3, 2015, Pages 772-785

  Venkatraman, Ganesh ^a   Benesch, Matthew G K ^a   Tang, Xiaoyun ^a   Dewald, Jay ^a   McMullen, Todd P W ^b   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autotaxin; Autotaxin inhibitors; Breast cancer; Chemoresistance; Doxorubicin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; LYSOPHOSPHATIDIC ACID; PEROXIREDOXIN 4; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; MESSENGER RNA; NFE2L2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LYSATE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYSOPHOSPHOLIPIDS; MICE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LYSOPHOSPHATIDIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84937111999     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-262659     Document Type: Article

References (74)

1. Gonzalez-Angulo, A. M., Morales-Vasquez, F., and Hortobagyi, G. N. (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22
2. Lage, H. (2008) An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 65, 3145-3167
3. Bidard, F. C., Vincent-Salomon, A., Gomme, S., Nos, C., de Rycke, Y., Thiery, J. P., Sigal-Zafrani, B., Mignot, L., Sastre-Garau, X., and Pierga, J. Y.; Institut Curie Breast Cancer Study Group. (2008) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306-3311
4. Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H., and Pantel, K. (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80-86
5. Meads, M. B., Gatenby, R. A., and Dalton, W. S. (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674
6. Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., Hallett, M., and Park, M. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527
7. Nefedova, Y., Landowski, T. H., and Dalton, W. S. (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175-1182
8. Brindley, D. N., Lin, F. T., and Tigyi, G. J. (2013) Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta 1831, 74-85
9. Benesch, M. G., Ko, Y. M., McMullen, T. P., and Brindley, D. N. (2014) Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 588, 2712-2727
10. Kehlen, A., Lauterbach, R., Santos, A. N., Thiele, K., Kabisch, U., Weber, E., Riemann, D., and Langner, J. (2001) IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 123, 147-154
11. Nikitopoulou, I., Oikonomou, N., Karouzakis, E., Sevastou, I., Nikolaidou-Katsaridou, N., Zhao, Z., Mersinias, V., Armaka, M., Xu, Y., Masu, M., Mills, G. B., Gay, S., Kollias, G., and Aidinis, V. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925-933
12. Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., and Luster, A. D. (2008) The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14, 45-54
13. Hozumi, H., Hokari, R., Kurihara, C., Narimatsu, K., Sato, H., Sato, S., Ueda, T., Higashiyama, M., Okada, Y., Watanabe, C., Komoto, S., Tomita, K., Kawaguchi, A., Nagao, S., and Miura, S. (2013) Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Lab. Invest. 93, 508-519
14. Euer, N., Schwirzke, M., Evtimova, V., Burtscher, H., Jarsch, M., Tarin, D., and Weidle, U. H. (2002) Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res. 22(2A), 733-740
15. Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., Chun, J., and Yun, C. C. (2009) The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 136, 1711-1720
16. Cooper, A. B., Wu, J., Lu, D., and Maluccio, M. A. (2007) Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer? J. Gastrointest. Surg. 11, 1628-1634, discussion 1634-1635
17. Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G., Coombes, K., Muller, W., Hung, M. C., Perou, C. M., Lee, A. V., Fang, X., and Mills, G. B. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539-550
18. Popnikolov, N. K., Dalwadi, B. H., Thomas, J. D., Johannes, G. J., and Imagawa, W. T. (2012) Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma. Tumour Biol. 33, 2237-2243
19. Gaetano, C. G., Samadi, N., Tomsig, J. L., Macdonald, T. L., Lynch, K. R., and Brindley, D. N. (2009) Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol. Carcinog. 48, 801-809
20. Boucharaba, A., Serre, C. M., Grès, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., Clézardin, P., and Peyruchaud, O. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714-1725
21. Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clézardin, P., and Peyruchaud, O. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA 103, 9643-9648
22. Benesch, M. G., Tang, X., Maeda, T., Ohhata, A., Zhao, Y. Y., Kok, B. P., Dewald, J., Hitt, M., Curtis, J. M., McMullen, T. P., and Brindley, D. N. (2014) Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28, 2655-2666
23. Bhave, S. R., Dadey, D. Y., Karvas, R. M., Ferraro, D. J., Kotipatruni, R. P., Jaboin, J. J., Hallahan, A. N., Dewees, T. A., Linkous, A. G., Hallahan, D. E., and Thotala, D. (2013) Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines. Front. Oncol. 3, 236
24. Samadi, N., Bekele, R., Capatos, D., Venkatraman, G., Sariahmetoglu, M., and Brindley, D. N. (2011) Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 93, 61-70
25. Su, S. C., Hu, X., Kenney, P. A., Merrill, M. M., Babaian, K. N., Zhang, X. Y., Maity, T., Yang, S. F., Lin, X., and Wood, C. G. (2013) Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res. 19, 6461-6472
26. Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., Fells, J. I., Perygin, D., Parrill, A. L., Tigyi, G., and Prestwich, G. D. (2009) Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69, 5441-5449
27. Saga, H., Ohhata, A., Hayashi, A., Katoh, M., Maeda, T., Mizuno, H., Takada, Y., Komichi, Y., Ota, H., Matsumura, N., Shibaya, M., Sugiyama, T., Nakade, S., and Kishikawa, K. (2014) A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS ONE 9, e93230
28. Jaramillo, M. C., and Zhang, D. D. (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179-2191
29. Hooks, S. B., Santos, W. L., Im, D. S., Heise, C. E., Macdonald, T. L., and Lynch, K. R. (2001) Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Biol. Chem. 276, 4611-4621
30. Pilquil, C., Dewald, J., Cherney, A., Gorshkova, I., Tigyi, G., English, D., Natarajan, V., and Brindley, D. N. (2006) Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. J. Biol. Chem. 281, 38418-38429
31. Wang, X. J., Hayes, J. D., and Wolf, C. R. (2006) Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 66, 10983-10994
32. Furukawa, M., and Xiong, Y. (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 25, 162-171
33. Trinkle-Mulcahy, L., Boulon, S., Lam, Y. W., Urcia, R., Boisvert, F. M., Vandermoere, F., Morrice, N. A., Swift, S., Rothbauer, U., Leonhardt, H., and Lamond, A. (2008) Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes. J. Cell. Biol. 183, 223-239
34. Samadi, N., Gaetano, C., Goping, I. S., and Brindley, D. N. (2009) Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28, 1028-1039
35. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108
36. Lohoff, M., Prechtl, S., Sommer, F., Roellinghoff, M., Schmitt, E., Gradehandt, G., Rohwer, P., Stride, B. D., Cole, S. P., and Deeley, R. G. (1998) A multidrug-resistance protein (MRP)-like transmembrane pump is highly expressed by resting murine T helper (Th) 2, but not Th1 cells, and is induced to equal expression levels in Th1 and Th2 cells after antigenic stimulation in vivo. J. Clin. Invest. 101, 703-710
37. Krech, T., Scheuerer, E., Geffers, R., Kreipe, H., Lehmann, U., and Christgen, M. (2012) ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. Cancer Lett. 315, 153-160
38. Chen, M., Towers, L. N., and O'Connor, K. L. (2007) LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell Physiol. 292, C1927-C1933
39. Hayashi, A., Suzuki, H., Itoh, K., Yamamoto, M., and Sugiyama, Y. (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem. Biophys. Res. Commun. 310, 824-829
40. Ji, L., Li, H., Gao, P., Shang, G., Zhang, D. D., Zhang, N., and Jiang, T. (2013) Nrf2 pathway regulates multidrug-resistanceassociated protein 1 in small cell lung cancer. PLoS ONE 8, e63404
41. Singh, A., Wu, H., Zhang, P., Happel, C., Ma, J., and Biswal, S. (2010) Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol. Cancer Ther. 9, 2365-2376
42. Nguyen, T., Sherratt, P. J., Huang, H. C., Yang, C. S., and Pickett, C. B. (2003) Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J. Biol. Chem. 278, 4536-4541
43. Shen, G., and Kong, A. N. (2009) Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm. Drug Dispos. 30, 345-355
44. Sporn, M. B., and Liby, K. T. (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12, 564-571
45. Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., Wong, P. K., and Zhang, D. D. (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29, 1235-1243
46. DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., Scrimieri, F., Winter, J. M., Hruban, R. H., Iacobuzio-Donahue, C., Kern, S. E., Blair, I. A., and Tuveson, D. A. (2011) Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109
47. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., and Motohashi, H. (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79
48. Singh, A., Happel, C., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., Boros, L. G., Gonzalez, F. J., Gabrielson, E., Wong, K. K., Girnun, G., and Biswal, S. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J. Clin. Invest. 123, 2921-2934
49. Shim, G. S., Manandhar, S., Shin, D. H., Kim, T. H., and Kwak, M. K. (2009) Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic. Biol. Med. 47, 1619-1631
50. Lau, A., Tian, W., Whitman, S. A., and Zhang, D. D. (2013) The predicted molecular weight of Nrf2: it is what it is not. Antioxid. Redox Signal. 18, 91-93
51. Harrison, E. M., McNally, S. J., Devey, L., Garden, O. J., Ross, J. A., and Wigmore, S. J. (2006) Insulin induces heme oxygenase-1 through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in renal cells. FEBS J. 273, 2345-2356
52. Yu, R., Chen, C., Mo, Y. Y., Hebbar, V., Owuor, E. D., Tan, T. H., and Kong, A. N. (2000) Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem. 275, 39907-39913
53. Sun, Z., Huang, Z., and Zhang, D. D. (2009) Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS ONE 4, e6588
54. Huang, H. C., Nguyen, T., and Pickett, C. B. (2000) Regulation of the antioxidant response element by protein kinase C- mediated phosphorylation of NF-E2-related factor 2. Proc. Natl. Acad. Sci. USA 97, 12475-12480
55. Juliano, R. L., and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162
56. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654
57. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95, 15665-15670
58. Gottesman, M. M., Fojo, T., and Bates, S. E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58
59. Lee, J. M., Hanson, J. M., Chu, W. A., and Johnson, J. A. (2001) Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J. Biol. Chem. 276, 20011-20016
60. Martin, D., Rojo, A. I., Salinas, M., Diaz, R., Gallardo, G., Alam, J., De Galarreta, C. M., and Cuadrado, A. (2004) Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J. Biol. Chem. 279, 8919-8929
61. Nakaso, K., Yano, H., Fukuhara, Y., Takeshima, T., Wada-Isoe, K., and Nakashima, K. (2003) PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett. 546, 181-184
62. Apopa, P. L., He, X., and Ma, Q. (2008) Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J. Biochem. Mol. Toxicol. 22, 63-76
63. Huang, H. C., Nguyen, T., and Pickett, C. B. (2002) Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 277, 42769-42774
64. Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., and Cuadrado, A. (2011) SCF/beta-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31, 1121-1133
65. Rojo, A. I., Sagarra, M. R., and Cuadrado, A. (2008) GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 105, 192-202
66. Salazar, M., Rojo, A. I., Velasco, D., de Sagarra, R. M., and Cuadrado, A. (2006) Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 281, 14841-14851
67. Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., and Hayes, J. D. (2013) Nrf2 is controlled by two distinct b-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765-3781
68. Zhang, D. D., and Hannink, M. (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23, 8137-8151
69. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N., and Chun, J. (2010) LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157-186
70. An, S., Bleu, T., Hallmark, O. G., and Goetzl, E. J. (1998) Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273, 7906-7910
71. Shida, D., Kitayama, J., Yamaguchi, H., Okaji, Y., Tsuno, N. H., Watanabe, T., Takuwa, Y., and Nagawa, H. (2003) Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63, 1706-1711
72. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008) Cancer-related inflammation. Nature 454, 436-444
73. Reuter, S., Gupta, S. C., Chaturvedi, M. M., and Aggarwal, B. B. (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49, 1603-1616
74. Gorrini, C., Baniasadi, P. S., Harris, I. S., Silvester, J., Inoue, S., Snow, B., Joshi, P. A., Wakeham, A., Molyneux, S. D., Martin, B., Bouwman, P., Cescon, D. W., Elia, A. J., Winterton-Perks, Z., Cruickshank, J., Brenner, D., Tseng, A., Musgrave, M., Berman, H. K., Khokha, R., Jonkers, J., Mak, T. W., and Gauthier, M. L. (2013) BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 210, 1529-1544